Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 195,72 pts
-0.26%


Last updated : 18/11/2026 - 13h33
🏠 Home   ➤    Stock news

Valneva shares at the bottom of the SBF 120, down 18.5% over three months

The Lyon-based vaccine maker ranks at the bottom of its index while the Paris market remains stable mid-session. The stock extends a decline that began several weeks ago and remains far from its medium- and long-term benchmarks.


Valneva shares at the bottom of the SBF 120, down 18.5% over three months

A stock at the bottom of the ranking, far from its moving averages

Valneva shares fell 1.92% to €2.50 at midday, while the SBF 120 gained 0.02%. This decline places the stock among the largest decliners in the index. The stock remains below its three moving averages: the gap is 0.71% with the MM20 (€2.52) and 11.59% with the MM200 (€2.83).

Over three months, the loss reaches 18.55%, compared with 3.44% over the week. The decline occurs in a session where the Paris market remains calm, with the 10-year OAT at 4.91% and a 1.56-point spread with the Bund remaining benchmarks watched for French debt. The previous day's pullback below the MM50 thus continues without any notable rebound.

Results for the first nine months expected on November 24

Valneva will publish its results for the first nine months of 2026 on November 24. At the release of the first-half 2026 results on August 13, the company had confirmed its outlook for the year despite the persistent impact of the geopolitical context on travel.

Among the risks cited on that occasion was the dependence on deliveries of IXIARO to the U.S. Department of Defense, whose timing remains uncertain.

The group also mentioned regulatory decisions expected within the following twelve months on its candidate against Lyme disease.

Over one month, the stock remains nearly stable (-0.67%), while the data on the duration of response to the Ixchiq vaccine, published on November 10, did not reverse the three-month trend. The support at €2.33 and the resistance at €2.68 frame the current trading range.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 65,8 millions d'euros
  • Quarterly revenue: 65,8 millions d'euros
  • Revenue growth: -32,6 %
  • EBITDA: -39,8 millions d'euros
  • EBITDA margin: -60,4 %
  • Net income: -63,3 millions d'euros
Guidance from the release
  • Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
  • Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
  • Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
  • Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
  • Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
  • Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
  • Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
  • Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours